Life Science Investing Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
Life Science Investing Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Life Science Investing Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
Life Science Investing Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
80 Mile PLC Secures 3 Strategic MOUs with Fortune 500 Energy Group, Ludoil, and JEnergy and moves to 100% of Ferrandina Biofuels Plant
Cotec Purchases Commercial Scale Salter Cyclone Multi-Gravity-Separator Unit to be Located at Corem Québec, Canada
